Abstract:Objective To explore the curative effect of epirubicin/cyclophosphamide (EC) and sequential weekly paclitaxel(wP) neoadjuvant chemotherapy (NC) on patients with HER2 negative breast cancer and the risk factors of recurrence and metastasis after treatment. Methods A total of 205 patients with primary unilateral HER2 negative breast cancer undergoing neoadjuvant chemotherapy between January 2017 and February 2020 were selected and were randomly divided into observation group (receiving EC-wP regimen, n=102) and control group ［receiving EC-T (taxotere) regimen, n=103］. The surgical treatment were performed after neoadjuvant chemotherapy for patients in two groups. The clinical curative effect and adverse reactions were compared between two groups. The patients were followed up for 2 years after operation to analyze the risk factors of disease recurrence and metastasis. Results The effective rate of NC in observation group was statistically higher than that in control group (76.47% vs 63.11%, P<0.05). There was no statistical difference in the incidence of side effects (thrombocytopenia, anemia, gastrointestinal reactions, liver function damage, renal function damage, lung function damage, cardiac function damage and alopecia) between two groups (P>0.05). The degree of neutropenia in observation group was slighter than that in control group (P<0.05). There was no statistical difference in 2-year progression-free survival rate between observation group and control group ［80.39% (82/102) vs 77.67% (80/103), P>0.05］. Logisitic regression analysis showed that tumor diameter ≥3 cm, high TNM staging and preoperative lymph node metastasis were the risk factors for recurrence and metastasis of breast cancer patients at 2 years after EC-wP neoadjuvant chemotherapy. Endocrine therapy was a protective factor for progression-free survival（P<0.05,P<0.01）. Conclusion EC-wP neoadjuvant chemotherapy has significant curative effect and high safety in the treatment of HER2 negative breast cancer.